银涂层近端胫骨巨假体用于肉瘤患者
本研究比较钛制与银涂层近端胫骨巨假体(MUTARS)在98例肉瘤或巨细胞瘤患者中的感染率,钛组42例感染率为16.7%,银组56例为8.9%,5年假体生存率银组90%、钛组84%,钛组37.5%患者最终截肢而银组仅1例(14.3%)。作者认为银涂层假体降低了感染率,且感染治疗侵袭性更小。
要点
- 钛组感染率16.7%,银组8.9%,银涂层假体降低感染率
- 5年假体生存率银组90%,钛组84%
- 钛组37.5%最终截肢,银组仅1例(14.3%)
核心结论
- 使用银涂层假体降低了相对较大且同质患者群体的感染率,且银涂层假体组感染治疗侵袭性更小。
研究设计与样本
- 本研究为比较钛制与银涂层巨假体(MUTARS)感染率的研究,纳入98例近端胫骨肉瘤或巨细胞瘤患者,钛组42例,银涂层组56例,并评估感染的治疗措施。
主要发现
- 主要终点感染率钛组为16.7%,银涂层组为8.9%。
- 5年假体生存率银涂层组为90%,钛组为84%。
- 钛组37.5%患者最终需截肢,银涂层组仅1例(14.3%)需截肢。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Proximal tibia arthroplasty is associated with high rates of infection. This study is the largest one that has compared the infection rates with titanium vs silver-coated megaprostheses in patients treated for sarcomas. METHODS: The infection rate in 98 patients with sarcoma or giant-cell tumor in the proximal tibia who underwent placement of a titanium (n = 42) or silver-coated (n = 56) megaprosthesis (MUTARS) was assessed, along with the treatments administered for any infection. RESULTS: As the primary end point of the study, the rates of infection were 16.7% in the titanium group and 8.9% in the silver group, resulting in 5-year prosthesis survival rates of 90% in the silver and 84% in the titanium group. Whereas in the titanium group 37.5% of patients ultimately had to undergo amputation in the present study, these mutilating surgical procedures were only necessary in the silver group in one patient (14.3%). CONCLUSION: The use of silver-coated prosthesis reduced the infection rate in a relatively large and homogeneous group of patients. In addition, less-aggressive treatment of infection was possible in the group with silver-coated prosthesis.
引用
- Hardes J, Henrichs MP, Hauschild G, et al. Silver-Coated Megaprosthesis of the Proximal Tibia in Patients With Sarcoma. J Arthroplasty. 2017. PMID: 28343825. doi:10.1016/j.arth.2017.02.054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。